Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 171

1.

Topical Application of Cinnamaldehyde Promotes Faster Healing of Skin Wounds Infected with Pseudomonas aeruginosa.

Ferro TAF, Souza EB, Suarez MAM, Rodrigues JFS, Pereira DMS, Mendes SJF, Gonzaga LF, Machado MCAM, Bomfim MRQ, Calixto JB, Arbiser JL, Monteiro-Neto V, André E, Fernandes ES.

Molecules. 2019 Apr 25;24(8). pii: E1627. doi: 10.3390/molecules24081627.

2.

Palladium based nanoparticles for the treatment of advanced melanoma.

Elsey J, Bubley JA, Zhu L, Rao S, Sasaki M, Pollack BP, Yang L, Arbiser JL.

Sci Rep. 2019 Mar 1;9(1):3255. doi: 10.1038/s41598-019-40258-6.

3.

Myofibroblast proliferation and heterogeneity are supported by macrophages during skin repair.

Shook BA, Wasko RR, Rivera-Gonzalez GC, Salazar-Gatzimas E, López-Giráldez F, Dash BC, Muñoz-Rojas AR, Aultman KD, Zwick RK, Lei V, Arbiser JL, Miller-Jensen K, Clark DA, Hsia HC, Horsley V.

Science. 2018 Nov 23;362(6417). pii: eaar2971. doi: 10.1126/science.aar2971.

PMID:
30467144
4.

Exploiting Honokiol-induced ER stress CHOP activation inhibits the growth and metastasis of melanoma by suppressing the MITF and β-catenin pathways.

Chiu CS, Tsai CH, Hsieh MS, Tsai SC, Jan YJ, Lin WY, Lai DW, Wu SM, Hsing HY, Arbiser JL, Sheu ML.

Cancer Lett. 2019 Feb 1;442:113-125. doi: 10.1016/j.canlet.2018.10.026. Epub 2018 Nov 1.

PMID:
30391358
5.

Antioxidants: Positive or Negative Actors?

Salehi B, Martorell M, Arbiser JL, Sureda A, Martins N, Maurya PK, Sharifi-Rad M, Kumar P, Sharifi-Rad J.

Biomolecules. 2018 Oct 25;8(4). pii: E124. doi: 10.3390/biom8040124. Review.

6.

Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials.

Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB.

Cancer. 2019 Jan 1;125(1):18-44. doi: 10.1002/cncr.31719. Epub 2018 Oct 3. Review.

PMID:
30281145
7.

Selenium unmasks protective iron armor: A possible defense against cutaneous inflammation and cancer.

Arbiser JL, Bonner MY, Ward N, Elsey J, Rao S.

Biochim Biophys Acta Gen Subj. 2018 May 28. pii: S0304-4165(18)30150-8. doi: 10.1016/j.bbagen.2018.05.018. [Epub ahead of print]

PMID:
29852199
8.

ROS modifiers and NOX4 affect the expression of the survivin-associated radio-adaptive response.

Murley JS, Arbiser JL, Weichselbaum RR, Grdina DJ.

Free Radic Biol Med. 2018 Aug 1;123:39-52. doi: 10.1016/j.freeradbiomed.2018.04.547. Epub 2018 Apr 13.

PMID:
29660403
9.

Targeting the Plasticity of Psoriasis.

Arbiser JL, Elsey J.

J Invest Dermatol. 2018 Apr;138(4):734-736. doi: 10.1016/j.jid.2017.11.030.

10.

Diablo: A Double-Edged Sword in Cancer?

Arbiser JL.

Mol Ther. 2018 Mar 7;26(3):678-679. doi: 10.1016/j.ymthe.2018.02.004. Epub 2018 Feb 20. No abstract available.

11.

Honokiol is a FOXM1 antagonist.

Halasi M, Hitchinson B, Shah BN, Váraljai R, Khan I, Benevolenskaya EV, Gaponenko V, Arbiser JL, Gartel AL.

Cell Death Dis. 2018 Jan 24;9(2):84. doi: 10.1038/s41419-017-0156-7.

12.

Peroxisome proliferator-activated receptor gamma (PPARγ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target.

Pleniceanu O, Shukrun R, Omer D, Vax E, Kanter I, Dziedzic K, Pode-Shakked N, Mark-Daniei M, Pri-Chen S, Gnatek Y, Alfandary H, Varda-Bloom N, Bar-Lev DD, Bollag N, Shtainfeld R, Armon L, Urbach A, Kalisky T, Nagler A, Harari-Steinberg O, Arbiser JL, Dekel B.

EMBO Mol Med. 2017 Dec;9(12):1763. doi: 10.15252/emmm.201708507. No abstract available.

13.

Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin.

Wang X, Beitler JJ, Huang W, Chen G, Qian G, Magliocca K, Patel MR, Chen AY, Zhang J, Nannapaneni S, Kim S, Chen Z, Deng X, Saba NF, Chen ZG, Arbiser JL, Shin DM.

Clin Cancer Res. 2018 Feb 15;24(4):858-869. doi: 10.1158/1078-0432.CCR-17-0345. Epub 2017 Nov 27.

14.

Overcoming Resistance to Cetuximab with Honokiol, A Small-Molecule Polyphenol.

Pearson HE, Iida M, Orbuch RA, McDaniel NK, Nickel KP, Kimple RJ, Arbiser JL, Wheeler DL.

Mol Cancer Ther. 2018 Jan;17(1):204-214. doi: 10.1158/1535-7163.MCT-17-0384. Epub 2017 Oct 20.

15.

Honokiol Increases CD4+ T Cell Activation and Decreases TNF but Fails to Improve Survival Following Sepsis.

Klingensmith NJ, Chen CW, Liang Z, Burd EM, Farris AB, Arbiser JL, Ford ML, Coopersmith CM.

Shock. 2018 Aug;50(2):178-186. doi: 10.1097/SHK.0000000000001021.

PMID:
29023360
16.

Evidence for biochemical barrier restoration: Topical solenopsin analogs improve inflammation and acanthosis in the KC-Tie2 mouse model of psoriasis.

Arbiser JL, Nowak R, Michaels K, Skabytska Y, Biedermann T, Lewis MJ, Bonner MY, Rao S, Gilbert LC, Yusuf N, Karlsson I, Fritz Y, Ward NL.

Sci Rep. 2017 Sep 11;7(1):11198. doi: 10.1038/s41598-017-10580-y.

17.

Regression of diffuse B-cell lymphoma of the leg with intralesional gentian violet.

Rao S, Morris R, Rice ZP, Arbiser JL.

Exp Dermatol. 2018 Jan;27(1):93-95. doi: 10.1111/exd.13418. Epub 2017 Nov 7.

18.

Targeting the duality of cancer.

Arbiser JL, Bonner MY, Gilbert LC.

NPJ Precis Oncol. 2017;1. pii: 23. doi: 10.1038/s41698-017-0026-x. Epub 2017 Jun 22.

19.

Treatment of Hailey-Hailey Disease With Low-Dose Naltrexone.

Albers LN, Arbiser JL, Feldman RJ.

JAMA Dermatol. 2017 Oct 1;153(10):1018-1020. doi: 10.1001/jamadermatol.2017.2446. Erratum in: JAMA Dermatol. 2017 Oct 1;153(10):1072.

20.

Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells.

Metts J, Bradley HL, Wang Z, Shah NP, Kapur R, Arbiser JL, Bunting KD.

Sci Rep. 2017 Jun 30;7(1):4447. doi: 10.1038/s41598-017-04796-1.

Supplemental Content

Loading ...
Support Center